- Home
- MVO vs ACRV Comparison
MVO vs ACRV Comparison
Compare MVO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- ACRV
- Stock Information
- Founded
- MVO 2006
- ACRV 2018
- Country
- MVO United States
- ACRV United States
- Employees
- MVO N/A
- ACRV N/A
- Industry
- MVO Oil & Gas Production
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- MVO Energy
- ACRV Health Care
- Exchange
- MVO Nasdaq
- ACRV Nasdaq
- Market Cap
- MVO 49.9M
- ACRV 47.8M
- IPO Year
- MVO N/A
- ACRV 2022
- Fundamental
- Price
- MVO $4.03
- ACRV $2.26
- Analyst Decision
- MVO
- ACRV Buy
- Analyst Count
- MVO 0
- ACRV 6
- Target Price
- MVO N/A
- ACRV $17.75
- AVG Volume (30 Days)
- MVO 55.1K
- ACRV 1.2M
- Earning Date
- MVO 01-01-0001
- ACRV 11-13-2025
- Dividend Yield
- MVO 17.46%
- ACRV N/A
- EPS Growth
- MVO N/A
- ACRV N/A
- EPS
- MVO 1.46
- ACRV N/A
- Revenue
- MVO N/A
- ACRV N/A
- Revenue This Year
- MVO N/A
- ACRV N/A
- Revenue Next Year
- MVO N/A
- ACRV $805.34
- P/E Ratio
- MVO $7.29
- ACRV N/A
- Revenue Growth
- MVO N/A
- ACRV N/A
- 52 Week Low
- MVO $8.85
- ACRV $1.05
- 52 Week High
- MVO $13.95
- ACRV $8.35
- Technical
- Relative Strength Index (RSI)
- MVO 17.95
- ACRV 58.68
- Support Level
- MVO $4.21
- ACRV $1.78
- Resistance Level
- MVO $4.50
- ACRV $2.35
- Average True Range (ATR)
- MVO 0.19
- ACRV 0.20
- MACD
- MVO -0.04
- ACRV 0.01
- Stochastic Oscillator
- MVO 0.00
- ACRV 69.83
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.